Schizophrenia



Esomeprazole for the Treatment of Negative Symptoms of Schizophrenia


Condition:   Schizophrenia
Intervention:   Drug: esomeprazole
Sponsors:   National Taiwan University Hospital;   National Taiwan University
Completed


Mindfulness and Cognition in Schizophrenia


Condition:   Schizophrenia
Intervention:   Behavioral: Mindfulness
Sponsors:   Centre Hospitalier Universitaire de Saint Etienne;   Fondation de l'Avenir
Not yet recruiting


Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia


Condition:   Schizophrenia
Interventions:   Drug: Levetiracetam;   Drug: Placebo
Sponsor:   VA Office of Research and Development
Not yet recruiting


An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia


Condition:   Schizophrenia
Intervention:   Drug: SEP-363856
Sponsor:   Sunovion
Recruiting


A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia


Condition:   Schizophrenia
Interventions:   Drug: SEP-363856;   Drug: Placebo - Cap
Sponsor:   Sunovion
Recruiting


A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia


Condition:   Schizophrenia
Interventions:   Drug: ASP4345;   Drug: Matching Placebo
Sponsor:   Astellas Pharma Global Development, Inc.
Completed


Aerobic Exercise for Cognition in Schizophrenia


Condition:   Schizophrenia
Interventions:   Behavioral: Aerobic Exercise;   Behavioral: Balance and Stretching
Sponsors:   VA Office of Research and Development;   Emory University
Recruiting


Factors Influencing Social Functioning of People With Schizophrenia


Condition:   Schizophrenia
Intervention:  
Sponsors:   University of Campania "Luigi Vanvitelli";   University of Turin, Italy;   University of Bari;   University of Genova
Completed


F17464 in Acute Schizophrenia Trial


Condition:   Schizophrenia
Interventions:   Drug: F17464;   Drug: Placebo
Sponsor:   Pierre Fabre Medicament
Completed


A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia


Condition:   Schizophrenia
Intervention:   Drug: Aripiprazole
Sponsor:   Otsuka Pharmaceutical Co., Ltd.
Completed


Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-Positive


Condition:   Schizophrenia
Interventions:   Other: Gluten Free Flour;   Other: Wheat Flour
Sponsor:   University of Maryland
Completed


A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients


Condition:   Schizophrenia
Interventions:   Drug: AQW051;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Completed


Insight in Persons Presenting Schizophrenia or Related Troubles During Hospitalization in Psychiatry


Condition:   Schizophrenia
Intervention:   Other: insight variation measure
Sponsor:   Centre Hospitalier Esquirol
Completed


Therapeutic Efficacy of Transcranial Magnetic Stimulation in Schizophrenia


Condition:   Schizophrenia
Intervention:   Device: Repetitive Transcranial Magnetic Stimulation
Sponsors:   Beth Israel Deaconess Medical Center;   Sidney R. Baer, Jr. Foundation
Completed


An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia


Condition:   Schizophrenia
Intervention:   Drug: Aripiprazole
Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
Active, not recruiting


Sensorimotor Gating in Schizophrenia


Condition:   Schizophrenia
Intervention:   Procedure: acoustic startle testing
Sponsor:   Emory University
Active, not recruiting


Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia


Condition:   Schizophrenia
Intervention:   Drug: AZD3480
Sponsor:   AstraZeneca
Completed


A Multicenter Study of NAP (AL-108) in Schizophrenia


Condition:   Schizophrenia
Interventions:   Drug: AL-108;   Drug: Placebo
Sponsors:   University of California, Los Angeles;   University of Maryland;   Washington University School of Medicine;   Massachusetts General Hospital;   Nathan Kline Institute for Psychiatric Research;   Columbia University;   Duke University;   Beth Israel Deaconess Medical Center
Completed


High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms


Condition:   Schizophrenia
Interventions:   Drug: Ziprasidone 80-160 mg/d;   Drug: Placebo;   Drug: Ziprasidone 160 mg/d
Sponsors:   Donald C. Goff, MD;   Pfizer
Completed


The Partners Genetics Collaborative Study of Schizophrenia


Condition:   Schizophrenia
Intervention:  
Sponsors:   Massachusetts General Hospital;   National Institute of Mental Health (NIMH)
Completed


Cognitive Remediation for Schizophrenia


Condition:   Schizophrenia
Intervention:   Behavioral: Computer Assisted Cognitive Remediation (CACR)
Sponsors:   University of Maryland;   National Institute of Mental Health (NIMH);   VISN 5 Mental Illness Research, Education and Clinical Center
Completed


Glycine vs Placebo for the Schizophrenia Prodrome


Condition:   Schizophrenia Prodrome
Interventions:   Drug: Glycine;   Drug: Placebo
Sponsors:   Yale University;   Glytech, Inc;   National Alliance for Research on Schizophrenia and Depression
Completed


Effects of RG1068 (Secretin) on Information Processing in Schizophrenia


Condition:   Schizophrenia
Intervention:   Drug: Subcutaneous Secretin
Sponsors:   Indiana University School of Medicine;   Shekhar, Anantha M.D., Ph.D.;   Repligen Corporation
Completed


A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia


Condition:   Schizophrenia
Intervention:   Drug: Clozapine
Sponsor:   Novartis
Completed


Trial of DMXB-A in Schizophrenia


Condition:   Schizophrenia
Interventions:   Drug: 3-2,4 dimethoxybenzylidene 75 or 150 mg bid;   Drug: Placebo
Sponsor:   VA Office of Research and Development
Recruiting

Refine Your Search Advanced Search